TABLE OF CONTENTS		
			
	
EXECUTIVE SUMMARY		
	?	OBJECTIVE	
	?	MARKET SCENARIO	
	?	EMERGING TECHNOLOGIES	
	
1	INTRODUCTION	
	1.1	KEY TAKE-AWAYS	
	1.2	REPORT DESCRIPTION	
	1.3	MARKETS COVERED	
	1.4	STAKEHOLDERS	
	1.5	RESEARCH METHODOLOGY	
	
2	SUMMARY	
	
3	MARKET OVERVIEW	
	3.1	INTRODUCTION	
	3.2	ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE	
	3.3	STAKEHOLDERS	
	3.4	CHALLENGES	
	3.4.1	GOVERNMENT REGULATIONS	
	3.4.2	PRICING PRESSURE, REIMBURSEMENTS, & THIRD-PARTY DEPENDENCE	
	3.4.3	PATENT LITIGATIONS	
	3.4.4	PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES	
	3.5	CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS	
	3.6	PATENT ANALYSIS	
	 		
4	MARKET DYNAMICS	
	4.1	INTRODUCTION	
	4.2	DRIVERS	
	4.2.1	PATENT EXPIRATION OF DRUGS	
	4.2.2	NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS & BIOPHARMACEUTICALS	
	4.2.3	REDUCE ATTRITION RATES & FASTER DRUG DISCOVERY/DEVELOPMENT PROCESSES	
	4.2.4	EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY	
	4.2.5	INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES	
	4.3	RESTRAINTS	
	4.3.1	DRUG FAILURES RAISE CONCERNS ON ROI	
	4.3.2	U.S. HEALTHCARE REFORMS	
	4.4	OPPORTUNITIES	
	4.4.1	HOME-CARE DRUG DELIVERY DEVICES & SELF-ADMINISTRATION	
	4.4.2	NICHE THERAPEUTIC AREAS	
	4.4.3	WELLNESS PRODUCTS	

5	CONTROLLED RELEASE TECHNOLOGY	
	5.1	INTRODUCTION	
	5.1.1	KEY MARKET PLAYERS	
	5.2	DRIVERS	
	5.2.1	CONTROLLED RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS	
	5.2.2	ONCE-A-DAY FORMULATIONS	
	5.2.3	COST EFFECTIVE	
	5.3	RESTRAINTS	
	5.3.1	LIMITED NUMBER OF MATERIALS	
	5.3.2	TECHNICAL BARRIERS	
	5.4	OPPORTUNITIES	
	5.4.1	PARTICULATE & CHRONOPHARMACOKINETIC SYSTEMS	
	5.4.2	MUCOADHESIVE DRUG DELIVERY	
	5.5	BIODEGRADABLE POLYMERS	
	5.6	HYDROGEL	
	5.7	MULTIPARTICULATE BEAD SYSTEMS	
	5.8	ION EXCHANGE RESINS	
	5.9	OSMOTIC PRESSURE CONTROLLED SYSTEMS	
	5.10	DISSOLUTION/DIFFUSION SYSTEMS	
	5.10.1	MATRIX SYSTEMS	
	5.10.2	RESERVOIR SYSTEMS	
	5.11	OTHERS	
	5.12	REGULATORY ENVIRONMENT	
	5.13	CONTROLLED RELEASE VS IMMEDIATE RELEASE FORMULATIONS	
	5.14	INNOVATIONS IN CONTROLLED RELEASE TECHNOLOGIES	
	5.15	BURNING ISSUES	
	5.16	WINNING IMPERATIVES	
	5.17	COMPETITIVE DEVELOPMENTS	
	
6	TARGETED DELIVERY	
	6.1	INTRODUCTION	
	6.1.1	KEY MARKET PLAYERS	
	6.2	DRIVERS & RESTRAINTS	
	6.2.1	INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS	
	6.2.2	LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR	
	6.2.3	HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS	
	6.3	OPPORTUNITY	
	6.3.1	NOVEL TARGETED DRUG DELIVERY SYSTEMS	
	6.4	TARGETING LIGANDS	
	6.4.1.1	Antibody fragment drug conjugate delivery	
	6.4.1.2	Antibody directed enzyme prodrug targeted delivery	
	6.4.1.3	Peptide-targeted delivery	
	6.4.1.4	Small molecule conjugate delivery	
	6.4.1.5	Others	
	6.5	NON-BIOLOGICAL TARGETING PLATFORMS	
	6.6	CURRENTLY MARKETED TARGETED THERAPIES	
	6.7	IMPACT OF TARGETED DRUG DELIVERY IN CANCER & OTHER CHRONIC CONDITIONS	
	6.8	INNOVATIONS	
	6.9	INDUSTRY INSIGHTS	
	6.10	WINNING IMPERATIVES	
	
7	ENCAPSULATION TECHNOLOGIES	
	7.1	INTRODUCTION	
	7.1.1	KEY MARKET PLAYERS	
	7.2	DRIVERS & RESTRAINTS	
	7.2.1	ENHANCED BIOAVAILABILITY	
	7.2.2	EXTENSIVE USAGE IN TASTE MASKING & FASTER DISSOLVING PILLS	
	7.2.3	ECONOMICALLY FEASIBLE	
	7.2.4	RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES	
	7.3	OPPORTUNITY	
	7.3.1	SOPHISTICATED MICROENCAPSULATION SYSTEMS	
	7.4	TASTE MASKING	
	7.5	FAST DISSOLVING PILLS	
	7.6	EVOLUTION OF ENCAPSULATION TECHNOLOGIES	
	7.7	APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY	
	7.8	INDUSTRY INSIGHTS	
	7.9	WINNING IMPERATIVES	
	7.10	COMPETITIVE DEVELOPMENTS	
	
8	TOPICAL FORMULATIONS	
	8.1	INTRODUCTION	
	8.1.1	KEY MARKET PLAYERS	
	8.2	DRIVERS & RESTRAINTS	
	8.2.1	BURN & WOUND TREATMENT	
	8.2.2	BYPASSING FIRST PASS EFFECT	
	8.2.3	CONVENIENCE FACTOR	
	8.2.4	USAGE IN LIMITED THERAPEUTIC AREAS	
	8.3	OPPORTUNITY	
	8.3.1	TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS	
	8.4	GEL TECHNOLOGY	
	8.5	MICROEMULSIONS	
	8.6	BIPHASIC SYSTEM	
	8.7	OTHERS	
	8.8	INDUSTRY INSIGHTS	
	8.9	WINNING IMPERATIVES	
	8.1	COMPETITIVE DEVELOPMENTS	
	
9	INHALER TECHNOLOGY	
	9.1	INTRODUCTION	
	9.1.1	KEY MARKET PLAYERS	
	9.2	DRIVERS & RESTRAINTS	
	9.2.1	INCREASE IN ASTHMA & COPD PATIENTS	
	9.2.2	TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN	
	9.2.3	EASE OF USE, SELF-ADMINISTRATION, & PAINLESS DRUG DELIVERY	
	9.2.4	FAILURE OF EXUBERA	
	9.3	OPPORTUNITY	
	9.3.1	APPLICATION IN NON-RESPIRATORY CONDITIONS	
	9.4	DRY POWDER INHALERS	
	9.5	METERED DOSE INHALERS	
	9.6	NEBULIZERS	
	9.7	EVOLUTION OF INHALER DEVICES	
	9.8	REGULATORY ENVIRONMENT	
	9.9	TECHNOLOGY INNOVATIONS	
	9.10	INDUSTRY INSIGHTS	
	9.11	WINNING IMPERATIVES	
	9.12	COMPETITIVE DEVELOPMENTS	
	
10	INJECTABLE DRUG DELIVERY	
	10.1	INJECTION DEVICES	
	10.1.1	KEY MARKET DYNAMICS	
	10.1.1.1	Drivers	
	10.1.1.1.1	Growth of self-administration therapies	
	10.1.1.1.2	Needle-stick legislation	
	10.1.1.1.3	Increasing acceptance by physicians and patients	
	10.1.1.1.4	Reducing cost of treatment	
	10.1.1.2	Restraints	
	10.1.1.2.1	Need of new drug formulation	
	10.1.1.3	Opportunities	
	10.1.1.3.1	Product differentiation through added functional features	
	10.1.1.3.2	Expansion to new areas	
	10.2	CRITERIA FOR SELECTION OF INJECTABLE DEVICE	
	10.3	KEY DEVELOPMENTS	
	10.3.1	DEVELOPMENT OF MICRONEEDLES	
	10.3.2	DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS	
	10.4	CONVENTIONAL INJECTABLES	
	10.5	PREFILLED SYRINGES (PFS)	
	10.5.1	KEY MARKET DYNAMICS	
	10.5.1.1	Drivers	
	10.5.1.1.1	Growing market for self-injection devices	
	10.5.1.1.2	Wastage control and cost reduction through less overfill	
	10.5.1.1.3	Ease of manufacture & convenient usability	
	10.5.1.2	Restraints	
	10.5.1.2.1	Threat from needle-free devices	
	10.5.1.2.2	Protecting product quality	
	10.5.2	GLASS PFS	
	10.5.3	PLASTIC PFS	
	10.6	SELF INJECTION DEVICES	
	10.6.1	AUTO INJECTORS	
	10.6.1.1	Reusable auto-injectors	
	10.6.1.2	Disposable auto-injectors	
	10.6.2	PEN INJECTORS	
	10.6.2.1	Reusable pen injectors	
	10.6.2.2	Disposable pen injectors	
	10.6.3	NEEDLE-FREE INJECTORS (NFI)	
	10.6.3.1	Reusable NFIs	
	10.6.3.2	Disposable NFIs	
	10.7	OTHERS	
	
11	TRANSDERMAL PATCH	
	11.1	INTRODUCTION	
	11.1.1	KEY MARKET PLAYERS	
	11.2	DRIVERS	
	11.2.1	REDUCED SIDE EFFECTS & BETTER EFFICACY	
	11.2.2	CONVENIENT & LESS PAINFUL	
	11.3	RESTRAINTS	
	11.3.1	RECALL OF DURAGESIC & NEGATIVE PUBLICITY OF ORTHO EVRA PATCH	
	11.3.2	LOW SKIN PERMEABILITY OF DRUGS	
	11.4	OPPORTUNITIES	
	11.4.1	NEW PRODUCTS	
	11.4.1.1	Contraceptive patch	
	11.4.1.2	Pain management patch	
	11.4.1.3	Estrogen/hormone replacement patch	
	11.5	INDUSTRY INSIGHTS	
	11.6	WINNING IMPERATIVES	
	11.7	COMPETITIVE DEVELOPMENTS	
	
12	IMPLANTABLE DRUG DELIVERY	
	12.1	INTRODUCTION	
	12.2	DRIVERS & RESTRAINTS	
	12.2.1	SELECTIVE DRUG DELIVERY & LOW AMOUNT OF ACTIVE DRUG INGREDIENT	
	12.2.2	DOSING ADMINISTRATION NOT REQUIRED	
	12.2.3	INCONVENIENCE	
	12.3	OPPORTUNITY	
	12.3.1	TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS	
	12.4	CORONARY (DRUG ELUTING) STENTS	
	12.5	IMPLANTABLE INFUSION PUMPS	
	12.6	OCULAR IMPLANTS & OTHERS	
	12.7	INDUSTRY INSIGHTS	
	12.8	WINNING IMPERATIVES	
	
13	LIPOSOMAL DRUG DELIVERY	
	13.1	INTRODUCTION	
	13.2	DRIVERS & RESTRAINTS	
	13.2.1	ENHANCED USAGE IN CANCER	
	13.2.2	EASY MANUFACTURING PROCEDURE & COST EFFECTIVENESS	
	13.2.3	SIDE EFFECTS	
	13.3	OPPORTUNITY	
	13.3.1	NANOSCALE LIPOSOME DRUG DELIVERY	
	13.4	INDUSTRY INSIGHTS	
	13.5	WINNING IMPERATIVES	
	13.6	COMPETITIVE DEVELOPMENTS	
	
14	PEGYLATION TECHNOLOGIES	
	14.1	INTRODUCTION	
	14.2	DRIVERS & RESTRAINTS	
	14.2.1	BIOLOGICAL DRUGS	
	14.2.2	ENHANCED PHARMACOKINETIC PROPERTIES & REDUCED DOSAGE	
	14.2.3	EXPENSIVE MANUFACTURING PROCEDURE	
	14.3	OPPORTUNITY	
	14.3.1	TECHNOLOGICAL ADVANCES	
	14.4	INDUSTRY INSIGHTS	
	14.5	WINNING IMPERATIVES	
	
15	COMPETITIVE LANDSCAPE	
	15.1	INTRODUCTION	
	15.2	ANALYSIS OF TOP PLAYERS	
	15.2.1	STRATEGY	
	15.2.2	INJECTABLE DRUG DELIVERY DEVICES MARKET SHARE	
	15.2.2.1	Top injectable drug delivery device companies & revenues, by segment	
	15.3	WINNING IMPERATIVES	
	15.3.1	ALLIANCES	
	15.3.2	POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY	
	15.3.3	SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS	
	15.4	STRATEGIC RECOMMENDATIONS	
	
16	GEOGRAPHIC ANALYSIS	
	16.1	INTRODUCTION	
	16.2	NORTH AMERICA	
	16.3	EUROPE	
	16.4	ASIA	
	16.5	REST OF THE WORLD (ROW)	
	16.6	DECISION SUPPORT DATABASE	
	
17	COMPANY PROFILES	
	17.1	3M COMPANY	
	17.1.1	OVERVIEW	
	17.1.2	FINANCIALS	
	17.1.3	PRODUCTS & SERVICES	
	17.1.4	STRATEGY	
	17.1.5	DEVELOPMENTS	
	17.2	ALKERMES, INC	
	17.2.1	OVERVIEW	
	17.2.2	FINANCIALS	
	17.2.3	PRODUCTS & SERVICES	
	17.2.4	STRATEGY	
	17.2.5	DEVELOPMENTS	
	17.3	ALTEA THERAPEUTICS INC.	
	17.3.1	OVERVIEW	
	17.3.2	PRODUCTS & SERVICES	
	17.3.3	STRATEGY	
	17.3.4	DEVELOPMENTS	
	17.4	ANTARES PHARMA INC.	
	17.4.1	OVERVIEW	
	17.4.2	FINANCIALS	
	17.4.3	PRODUCTS & SERVICES	
	17.4.4	STRATEGY	
	17.4.5	DEVELOPMENTS	
	17.5	A.P. PHARMA, INC.	
	17.5.1	OVERVIEW	
	17.5.2	FINANCIALS	
	17.5.3	PRODUCTS & SERVICES	
	17.5.4	STRATEGY	
	17.5.5	DEVELOPMENTS	
	17.6	APPLIED PHARMA	
	17.6.1	OVERVIEW	
	17.6.2	PRODUCTS & SERVICES	
	17.6.3	STRATEGY	
	17.6.4	DEVELOPMENTS	
	17.7	ARADIGM CORPORATION	
	17.7.1	OVERVIEW	
	17.7.2	FINANCIALS	
	17.7.3	PRODUCTS & SERVICES	
	17.7.4	STRATEGY	
	17.7.5	DEVELOPMENTS	
	17.8	BAXTER BIOPHARMA	
	17.8.1	OVERVIEW	
	17.8.2	PRODUCTS & SERVICES	
	17.8.3	FINANCIALS	
	17.8.4	STRATEGY	
	17.8.5	DEVELOP0MENTS	
	17.9	BECTON, DICKINSON AND COMPANY	
	17.9.1	OVERVIEW	
	17.9.2	PRODUCT & SERVICES	
	17.9.3	FINANCIALS	
	17.9.4	STRATEGY	
	17.9.5	DEVELOPMENTS	
	17.10	BIOJECT INC.	
	17.10.1	OVERVIEW	
	17.10.2	FINANCIALS	
	17.10.3	PRODUCTS & SERVICES	
	17.10.4	STRATEGY	
	17.10.5	DEVELOPMENTS	
	17.11	BIOVAIL CORPORATION  (VALEANT PHARMACEUTICALS INTERNATIONAL INC.)	
	17.11.1	OVERVIEW	
	17.11.2	PRODUCTS & SERVICES	
	17.11.3	FINANCIALS	
	17.11.4	STRATEGY	
	17.11.5	DEVELOPMENTS	
	17.12	CIMA LABS INC.	
	17.12.1	OVERVIEW	
	17.12.2	PRODUCTS & SERVICES	
	17.12.3	STRATEGY	
	17.12.4	DEVELOPMENTS	
	17.13	ELAN CORPORATION PLC.	
	17.13.1	OVERVIEW	
	17.13.2	FINANCIALS	
	17.13.3	PRODUCTS & SERVICES	
	17.13.4	STRATEGY	
	17.13.5	DEVELOPMENTS	
	17.14	ENDO PHARMACEUTICALS	
	17.14.1	OVERVIEW	
	17.14.2	FINANCIALS	
	17.14.3	PRODUCTS & SERVICES	
	17.14.4	STRATEGY	
	17.14.5	DEVELOPMENTS	
	17.15	EURAND PHARMACEUTICALS	
	17.15.1	OVERVIEW	
	17.15.2	FINANCIALS	
	17.15.3	PRODUCTS & SERVICES	
	17.15.4	STRATEGY	
	17.15.5	DEVELOPMENTS	
	17.16	FLAMEL TECHNOLOGIES, INC	
	17.16.1	OVERVIEW	
	17.16.2	FINANCIALS	
	17.16.3	PRODUCTS & SERVICES	
	17.16.4	STRATEGY	
	17.16.5	DEVELOPMENTS	
	17.17	JOHNSON & JOHNSON LTD.	
	17.17.1	OVERVIEW	
	17.17.2	FINANCIALS	
	17.17.3	PRODUCTS & SERVICES	
	17.17.4	STRATEGY	
	17.17.5	DEVELOPMENTS	
	17.18	KV PHARMACEUTICAL	
	17.18.1	OVERVIEW	
	17.18.2	FINANCIALS	
	17.18.3	PRODUCTS & SERVICES	
	17.18.4	STRATEGY	
	17.18.5	DEVELOPMENTS	
	17.19	LABOPHARM INC.	
	17.19.1	OVERVIEW	
	17.19.2	FINANCIALS	
	17.19.3	PRODUCTS & SERVICES	
	17.19.4	STRATEGY	
	17.19.5	DEVELOPMENTS	
	17.20	NANOPASS TECHNOLOGIES LTD.	
	17.20.1	OVERVIEW	
	17.20.2	PRODUCTS & SERVICES	
	17.20.3	STRATEGY	
	17.20.4	DEVELOPMENTS	
	17.21	NEKTAR THERAPEUTICS	
	17.21.1	OVERVIEW	
	17.21.2	FINANCIALS	
	17.21.3	PRODUCTS & SERVICES	
	17.21.4	STRATEGY	
	17.21.5	DEVELOPMENTS	
	17.22	QLT INC.	
	17.22.1	OVERVIEW	
	17.22.2	FINANCIALS	
	17.22.3	PRODUCTS & SERVICES	
	17.22.4	STRATEGY	
	17.22.5	DEVELOPMENTS	
	17.23	SKYEPHARMA PLC.	
	17.23.1	OVERVIEW	
	17.23.2	FINANCIALS	
	17.23.3	PRODUCTS & SERVICES	
	17.23.4	STRATEGY	
	17.23.5	DEVELOPMENTS	
	17.24	SURMODICS, INC.	
	17.24.1	OVERVIEW	
	17.24.2	PRODUCTS & SERVICES	
	17.24.3	FINANCIALS	
	17.24.4	STRATEGY	
	17.24.5	DEVELOPMENTS	
	17.25	VECTURA GROUP PLC	
	17.25.1	OVERVIEW	
	17.25.2	FINANCIALS	
	17.25.3	PRODUCTS & SERVICES	
	17.25.4	STRATEGY	
	17.25.5	DEVELOPMENTS	
	17.26	YPSOMED HOLDING AG	
	17.26.1	OVERVIEW	
	17.26.2	FINANCIALS	
	17.26.3	PRODUCTS & SERVICES	
	17.26.4	STRATEGY	
	17.26.5	DEVELOPMENTS	
	17.27	ZOGENIX, INC.	
	17.27.1	OVERVIEW	
	17.27.2	PRODUCTS & SERVICES	
	17.27.3	STRATEGY	
	17.27.4	DEVELOP0MENTS	
	
APPENDIX		
	?	U.S. PATENTS	
	?	EUROPE PATENTS	
	?	JAPAN PATENTS	
			
	 		
	
LIST OF TABLES		
	
1	TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS	
	2008 – 2015 ($MILLION)		
2	DRUGS SET FOR PATENT EXPIRATION (2010 – 2012)	
3	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
4	GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015  ($MILLION)	
5	GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
6	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
7	GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY	
	2008 – 2015 ($MILLION)		
8	GLOBAL HYDROGEL MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
9	GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
10	GLOBAL ION EXCHANGE RESINS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
11	GLOBAL OSMOTIC PRESSURE CONTROLLED SYSTEMS MARKET,	
	BY GEOGRAPHY 2008 – 2015 ($MILLION)		
12	GLOBAL DISSOLUTION/DIFFUSION SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
13	GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
14	GLOBAL RESERVOIR SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
15	GLOBAL OTHER CONTROLLED RELEASE SYSTEMS MARKET,	
	BY GEOGRAPHY 2008 – 2015 ($MILLION)		
16	GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
17	GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
18	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
19	GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
20	GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
21	GLOBAL ANTIBODY FRAGMENT CONJUGATE DELIVERY MARKET,	
	BY GEOGRAPHY 2008 – 2015 ($MILLION)		
22	GLOBAL ANTIBODY ENZYME DIRECTED PRODRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
23	GLOBAL PEPTIDE TARGETED DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
24	GLOBAL SMALL MOLECULE CONJUGATE DELIVERY MARKET,	
	BY GEOGRAPHY 2008 – 2015 ($MILLION)		
25	GLOBAL OTHER TARGETING LIGANDS BASED DELIVERY MARKET,	
	BY GEOGRAPHY 2008 – 2015 ($MILLION)		
26	GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET,	
	BY GEOGRAPHY 2008 – 2015 ($MILLION)		
27	GLOBAL ENCAPSULATION TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
28	GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
29	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
30	GLOBAL ENCAPSULATION MARKET IN TASTE MASKING, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
31	GLOBAL ENCAPSULATION MARKET IN FAST DISSOLVING,	
	BY GEOGRAPHY 2008 – 2015 ($MILLION)		
32	GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
33	GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY	
	(2008 – 2015)		
34	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
35	GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
36	GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
37	GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
38	GLOBAL OTHER TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($ MILLION)	
39	GLOBAL INHALER TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
40	GLOBAL INHALER TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
41	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
42	GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY	
	2008 – 2015 ($MILLION)		
43	GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY	
	2008 – 2015 ($MILLION)		
44	GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
45	GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
46	GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET,	
	BY GEOGRAPHY 2008-2015 ($MILLION)		
47	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
48	GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
49	GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
50	GLOBAL PREFILLED SYRINGES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
51	GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS	
	2008 – 2015 ($MILLION)		
52	GLOBAL SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY	
	2008 – 2015 ($MILLION)		
53	GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
54	GLOBAL AUTO INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
55	GLOBAL PEN INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
56	GLOBAL PEN INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
57	MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY	
58	GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)	
59	GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY GEOGRAPHY	
	2008 – 2015 ($MILLION)		
60	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
61	GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET,	
	BY PRODUCTS (2008 – 2015)		
62	GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET,	
	BY GEOGRAPHY 2008 – 2015 ($MILLION)		
63	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
64	GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)	
65	GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY	
	2008 – 2015 ($MILLION)		
66	GLOBAL OCULAR IMPLANTS & OTHERS MARKET, BY GEOGRAPHY	
	2008 – 2015 ($MILLION)		
67	GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY	
	2008 – 2015 ($MILLION)		
68	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
69	GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY	
	2008 – 2015 ($MILLION)		
70	IMPACT ANALYSIS OF KEY MARKET DYNAMICS	
71	REVENUE ANALYSIS (2008 – 2009)	
72	ELAN TOTAL REVENUES BY DRUG (2008 – 2010)	
73	ALKERMES TOTAL REVENUES, BY DRUG (2008 – 2010)	
74	R&D EXPENDITURE (2008 – 2009)	
75	ELAN’S PIPELINE DRUGS	
76	BIOVAIL’S PIPELINE DRUGS	
77	ALKERMES’S PIPELINE DRUGS	
78	NEKTAR’S PIPELINE DRUGS	
79	SKYE PHARMA’S PIPELINE DRUGS	
80	TOP COMPANIES & THEIR STRATEGIES	
81	BECTON DICKINSON – TOTAL REVENUES, BY SEGMENT ($MILLION)	
82	BAXTER BIOPHARMA REVENUES, BY SEGMENT	
83	YPSOMED - TOTAL REVENUES, BY SEGMENT ($MILLION)	
84	TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION	
	(2008 – 2015)		
85	NORTH AMERICAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET,	
	BY SEGMENT		
86	EUROPEAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET,	
	BY SEGMENT		
87	ASIAN TOP 10 DRUG DELIVERY TECHNOLOGIES	
88	REST OF THE WORLD TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET	
89	MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY (2009)	
90	OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY (2009)	
91	DIABETES PREVALENCE, BY GEOGRAPHY (2009)	
92	CANCER PREVALENCE, BY GEOGRAPHY (2009)	
93	RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY (2009)	
94	ANEMIA PREVALENCE, BY GEOGRAPHY (2009)	
95	HEPATITIS-C PREVALENCE, BY GEOGRAPHY (2009)	
96	CROHN’S DISEASE PREVALENCE, BY GEOGRAPHY (2009)	
97	PSORIASIS PREVALENCE, BY GEOGRAPHY (2009)	
98	TOTAL REVENUES & R&D EXPENDITURE	
99	TOTAL REVENUES, BY GEOGRAPHY	
100	TOTAL REVENUES (2006 – 2010)	
101	SEGMENT SPECIFIC REVENUES ($MILLION)	
102	TOTAL REVENUES & R&D EXPENDITURE ($MILLION)	
103	TOTAL REVENUES, BY GEOGRAPHY	
104	REVENUES, BY SEGMENTS	
105	TOTAL REVENUES & NET INCOME ($MILLION)	
106	TOTAL REVENUES (2007 – 2009)	
107	BAXTER BIOPHARMA – TOTAL REVENUES & R&D EXPENSES ($MILLION)	
108	BAXTER BIOPHARMA – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)	
109	BAXTER BIOPHARMA – TOTAL REVENUES, BY SEGMENTS ($MILLION)	
110	BAXTER BIOPHARMA – TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENTS ($MILLION)	
111	BECTON DICKINSON – TOTAL REVENUES & R&D EXPENDITURE ($MILLION)	
112	BECTON DICKINSON – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)	
113	BECTON DICKINSON – TOTAL REVENUES, BY SEGMENTS ($MILLION)	
114	BECTON DICKINSON – TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENTS ($MILLION)	
115	TOTAL REVENUES & R&D EXPENDITURE	
116	REVENUES, BY SEGMENTS ($MILLION)	
117	TOTAL REVENUES & R&D EXPENDITURE ($MILLION)	
118	U.S REVENUES OF BIOVAIL, BY PRODUCTS ($MILLION)	
119	TOTAL PRODUCT REVENUES OF BIOVAIL PHARMACEUTICALS CANADA	
120	TOTAL REVENUES & R&D EXPENDITURE	
121	REVENUES, BY PRODUCTS	
122	TOTAL REVENUES & R&D EXPENDITURE	
123	TOTAL REVENUES & R&D EXPENDITURE ($MILLION)	
124	PRODUCT SALES, BY THERAPEUTIC AREA	
125	REVENUES & R&D EXPENDITURE	
126	TOTAL REVENUES & R&D EXPENDITURE	
127	REVENUES, BY BUSINESS SEGMENTS	
128	REVENUES, BY PRODUCTS	
129	REVENUES, BY GEOGRAPHY ($MILLION)	
130	TOTAL REVENUES & EXPENDITURE	
131	TOTAL REVENUES & R&D EXPENDITURE	
132	NEKTAR – TOTAL REVENUES & R&D EXPENSES	
133	NEKTAR – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)	
134	QLT – TOTAL REVENUES & R&D EXPENSES ($MILLION)	
135	QLT – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)	
136	TOTAL REVENUES & R&D EXPENSES ($MILLION)	
137	SURMODICS INC. – TOTAL REVENUES & R&D EXPENSES ($MILLION)	
138	SURMODICS INC. – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)	
139	SURMODICS INC. – TOTAL REVENUES, BY SEGMENTS ($MILLION)	
140	TOTAL REVENUES & R&D EXPENDITURE	
141	YPSOMED - TOTAL REVENUES & R&D EXPENSES ($MILLION)	
142	YPSOMED - TOTAL REVENUES, BY SEGMENTS ($MILLION)	
			
	 		
	
LIST OF FIGURES		
			
1	REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES	
2	TOP 10 DRUG DELIVERY TECHNOLOGIES – MARKET SHARE	
3	EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY	
4	ROLE OF DRUG DELIVERY TECHNOLOGIES IN  A DRUG LIFE CYCLE	
5	DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS	
6	DRUG DELIVERY MARKET STAKEHOLDERS	
7	IMPACT OF MARKET DRIVERS & RESTRAINTS	
8	COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES	
9	PATENT ANALYSIS, BY SEGMENTS (2004 – 2009)	
10	PATENT ANALYSIS, BY ASSIGNEE (2004 – 2009)	
11	COMMON REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/ DEVELOPMENT PROCESS	
12	EVOLUTION OF CONTROLLED RELEASE TECHNOLOGIES	
13	CONTROLLED RELEASE VS IMMEDIATE RELEASE	
14	TARGETED THERAPY TYPES	
15	EVOLUTION OF ENCAPSULATION TECHNOLOGIES	
16	ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY	
17	EVOLUTION OF INHALER TECHNOLOGY	
18	FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE	
19	COMPETITIVE DEVELOPMENTS (2007 – JUNE 2010)	
20	COMPETITIVE DEVELOPMENTS, BY SEGMENTS (2007 – JUNE 2010)	
21	REVENUE ANALYSIS (2008 – 2009)	
22	CONTROLLED RELEASE, DRUG FORMULATION – MARKET SHARE	
23	R&D EXPENDITURE (2008 – 2009)	
24	INJECTABLE DRUG DELIVERY DEVICES, MARKET SHARE	
25	TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET	
26	TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – NORTH AMERICA	
27	TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – EUROPE	
28	TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ASIA	
29	TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ROW